MedPath

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Phase 3
Terminated
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
MSA
Parkinson's Disease (PD)
Pure Autonomic Failure (PAF)
Interventions
Drug: Placebo
Registration Number
NCT03829657
Lead Sponsor
Theravance Biopharma
Brief Summary

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

Detailed Description

Phase 3, multi-center, randomized withdrawal study to evaluate the sustained benefit in efficacy and safety of ampreloxetine in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH. The study consists of 3 periods: (i) 16-week open-label (OL) treatment with ampreloxetine, (ii) 6-week randomized placebo-controlled treatment, and (iii) 2-week follow-up (only for patients who do not enroll in Study 0171 (long-term extension safety study)).

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
203
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ampreloxetineampreloxetineAfter completing the OL, participants randomized to ampreloxetine will receive single, oral, daily dose of active drug for a further 6 weeks.
ampreloxetine (Open Label (OL))ampreloxetineParticipants will receive ampreloxetine as a single, oral, daily dose of active drug for 16 weeks.
PlaceboPlaceboAfter completing the OL, participants randomized to Placebo will receive single, oral, daily dose of placebo for 6 weeks.
Primary Outcome Measures
NameTimeMethod
Proportion of Participants With Treatment Failure at Week 6 of RW Treatment Period6-week randomized withdrawal period (Week 16 to Week 22)

Treatment failure was defined as proportion of participants who met the following criteria at Week 6 following randomization: Change (worsening) from baseline in Question 1 of the Orthostatic Hypotension Symptom Assessment (OHSA#1) score of 1.0 point and worsening of disease severity as assessed by a 1-point change in Patient Global Impression of Severity (PGI-S). OHSA Question #1 assessed dizziness, lightheadedness, feeling faint, or feeling like you might blackout. PGI-S assessed patient's impression of disease severity.

Least squares mean here is the model-based proportion of participants with treatment failure using logistic regression.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (82)

Parkinson's Disease and Movement Disorders Center

🇺🇸

Boca Raton, Florida, United States

SFM Clinical Research, LLC

🇺🇸

Boca Raton, Florida, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

NorthShore University Health System

🇺🇸

Glenview, Illinois, United States

Krakowska Akademia Neurologii Sp. Zo.o. Centrum Neurologii Klinicznej

🇵🇱

Kraków, Poland

Hospital da Senhora da Oliveira Guimarães

🇵🇹

Guimarães, Portugal

Universitatsklinikum Tulln Abteilung fur Neurologie

🇦🇹

Tulln, Austria

Tartu University Hospital

🇪🇪

Tartu, Estonia

NEURO-CARE Sp. z o.o. Sp. Komandytowa

🇵🇱

Siemianowice Śląskie, Poland

Oregon Health & Science University

🇺🇸

Portland, Oregon, United States

Wake Forest University Baptist Health Sciences

🇺🇸

Winston-Salem, North Carolina, United States

University of Texas Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

Stanford Neuroscience Health Center

🇺🇸

Palo Alto, California, United States

Colorado Springs Neurological Associates, PC

🇺🇸

Colorado Springs, Colorado, United States

UC San Diego Movement Disorder Center

🇺🇸

La Jolla, California, United States

University of Cincinnati Medical Center (UCGNI)

🇺🇸

Cincinnati, Ohio, United States

Ohio State University - Wexner Medical Center

🇺🇸

Columbus, Ohio, United States

Praxis Dr. med. Christian Oehlwein

🇩🇪

Gera, Germany

Hospital del Mar

🇪🇸

Barcelona, Spain

Hospital de Cruces

🇪🇸

Bilbao, Vizcaya, Spain

Concord Hospital, Neurosciences Department

🇦🇺

Concord, New South Wales, Australia

East Tallinn Central Hospital

🇪🇪

Tallinn, Estonia

Odense Universitetshospital

🇩🇰

Odense, Denmark

Rabin Medical Center, Beilinson Campus

🇮🇱

Petah Tikva, Israel

Kaplan Medical Center

🇮🇱

Rehovot, Israel

Azienda Ospedaliera Universitaria Policlinico - Vittorio Emanuele (Presidio Gaspare Rodolico)

🇮🇹

Catania, Italy

AOU San Giovanni di Dio e Ruggi d'Aragona

🇮🇹

Salerno, Italy

Specjalistyczna Praktyka Lekarska, Prof. Grzegorz Opala

🇵🇱

Katowice, Poland

CNS-Campus Neurologico Senior

🇵🇹

Torres Vedras, Portugal

FSBI of Science Institute of Human Brain named after N .P. Bekhtereva of Russian Academy of Sciences

🇷🇺

Saint Petersburg, Russian Federation

City Neurological Center Sibneiromed, LLC

🇷🇺

Novosibirsk, Russian Federation

Royal Devon and Exeter Hospital NHS Trust

🇬🇧

Exeter, Devon, United Kingdom

The National Hospital for Neurology & Neurosurgery

🇬🇧

London, United Kingdom

Saint Petersburg State Budgetary Institution of Healthcare City Hospital #40 of Kurortnyi Region

🇷🇺

Saint Petersburg, Sestroretsk, Russian Federation

FSBI National Medical Research Centre of psychiatry and neurology named after V.M. Bekhterev of the MOH of the Russian Federation

🇷🇺

Saint Petersburg, Russian Federation

Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin

🇩🇪

Berlin, Germany

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Banner Sun Health Research Institute

🇺🇸

Sun City, Arizona, United States

Neurostudies, Inc

🇺🇸

Port Charlotte, Florida, United States

New York University Langone Health

🇺🇸

New York, New York, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

Georgetown University Hospital

🇺🇸

McLean, Virginia, United States

Inland Northwest Research

🇺🇸

Spokane, Washington, United States

The Royal Melbourne Hospital Neurology Department

🇦🇺

Parkville, Victoria, Australia

MHATNP Sv. Naum EAD Clinic of Neurological Diseases for Locomotor Disorders

🇧🇬

Sofia, Bulgaria

Toronto Western Hospital

🇨🇦

Toronto, Ontario, Canada

University of Calgary Teaching Research and Wellness Building

🇨🇦

Calgary, Alberta, Canada

Montreal Neurological Institute & Hospital

🇨🇦

Montreal, Quebec, Canada

Bispebjerg Hospital

🇩🇰

Copenhagen, Denmark

CHU de Nîmes - Hôpital Caremeau

🇫🇷

Nîmes, France

Charite - Campus Virchow-Klinikum, Klinik fur Neurologie

🇩🇪

Berlin, Germany

Semmelweis Egyetem, Neurologiai Klinika

🇭🇺

Budapest, Hungary

Tel Aviv Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

Universita di Bologna-Clinica Neurologica - Dipt di Scienze Neurologiche Ospedale Bellaria

🇮🇹

Bologna, Italy

Universita degli studi Gabriele D' Annunzio Chieti

🇮🇹

Chieti, Italy

Azienda Ospedaliero-Universitaria Pisana- Ospedale S. Chiara, U.O. di Neurologia - Neurofisiopatologia

🇮🇹

Pisa, Italy

Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico

🇮🇹

Milano, Italy

A.O. Santa Maria

🇮🇹

Terni, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS / Istituto di Neurologia - Ambulatorio Disturbi del Movimento

🇮🇹

Roma, Italy

Fondazione PTV - Policlinico Tor Vergata I U.0.C. Neurologia

🇮🇹

Roma, Italy

New Zealand Brain Research Institute

🇳🇿

Christchurch, New Zealand

FSBI Federal Sibirian Scientific and Clinical Center of Federal Medico-Biological Agency

🇷🇺

Krasnoyarsk, Russian Federation

State Budgetary Institution of Healthcare of Novosibirsk region City Clinical Hospital #34

🇷🇺

Novosibirsk, Russian Federation

Hospital Universitario Mutua de Terrasa

🇪🇸

Terrassa, Barcelona, Spain

Complejo Hospitalario de Navarra

🇪🇸

Pamplona, Navarra, Spain

Hospital Universitario de La Princesa

🇪🇸

Madrid, Spain

Communal Noncommercial Enterprise City Policlinic #9 of Kharkiv City Council

🇺🇦

Kharkiv, Ukraine

Cognition Health Unit 2

🇬🇧

Plymouth, Devon, United Kingdom

Salford Royal NHS Foundation Trust

🇬🇧

Salford, Greater Manchester, United Kingdom

Clinical Research Centre, William Harvey Heart Centre

🇬🇧

London, United Kingdom

King's College Hospital

🇬🇧

London, United Kingdom

Perron Institute for Neurological and Translational Science

🇦🇺

Nedlands, Western Australia, Australia

Clinical Trials Centre, Level 3 Monash Health Translational Precinct Building Monash Medical Centre

🇦🇺

Clayton, Victoria, Australia

Re:Cognition Health Ltd

🇬🇧

London, United Kingdom

University of Kansas Medical Center Research Institute, Inc.

🇺🇸

Kansas City, Kansas, United States

Astra Team Clinic

🇪🇪

Tallinn, Estonia

Medizinische Universitat Innsbruck, Abteilung fur Neurologie

🇦🇹

Innsbruck, Austria

Instytut Zdrowia dr Boczarska-Jedynak

🇵🇱

Oswiecim, Poland

ETG Warszawa

🇵🇱

Warszawa, Poland

Specjalistyczne Gabinety sp. z o.o.

🇵🇱

Warszawa, Poland

Communal Noncommercial Enterprise of Lviv Regional Council Lviv Regional Clinical Hospital

🇺🇦

Lviv, Ukraine

Communal Institution Acad. O.I. Yuschenko VRPsH Vinnytsia M.I. Pyrogov NMU Ch of ND with the Course of Neurosurgery

🇺🇦

Vinnytsia, Ukraine

© Copyright 2025. All Rights Reserved by MedPath